NEW YORK – Pillar Biosciences and AstraZeneca said Tuesday that they have partnered to expand next-generation sequencing-based liquid biopsy testing in Europe.

纽约——支柱生物科学公司（Pillar Biosciences）和阿斯利康（AstraZeneca）周二表示，他们已合作在欧洲扩大下一代基于测序的液体活检检测。

In a statement, the firms said they aim to rapidly identify tumors with clinically actionable genomic alterations using Pillar's OncoReveal Core LBx, Essential LBx, and Fusion LBx research-use-only kits.

在一份声明中，这些公司表示，他们的目标是使用Pillar的OncoReveal Core LBx、Essential LBx和Fusion LBx research仅使用试剂盒快速鉴定具有临床可行基因组改变的肿瘤。

Financial and other terms are 'confidential,' a Pillar spokesperson said in an email, 'but the companies will collaborate to improve access to liquid biopsy testing and to drive health equity.'

支柱组织发言人在一封电子邮件中说，财务和其他条款是“保密的”，但两家公司将合作改进液体活检检测的渠道，并推动健康公平

'These kit-based methods allow a broad range of laboratories to perform high-quality NGS testing, which improves patient access to targeted therapies,' John Longshore, AstraZeneca's head of scientific affairs for global oncology diagnostics, said in a statement. 'Pillar Biosciences sequencing panels provide rapid, simplified NGS workflows and bioinformatics, which are ideal to supporting our global efforts.'.

阿斯利康全球肿瘤学诊断科学事务负责人约翰·朗肖尔（JohnLongshore）在一份声明中说：“这些基于试剂盒的方法允许广泛的实验室进行高质量的NGS检测，从而改善患者获得靶向治疗的机会。”支柱生物科学测序小组提供了快速，简化的NGS工作流程和生物信息学，是支持我们全球努力的理想选择。”。

Pillar's Core LBx panel interrogates 104 genes in circulating, cell-free tumor DNA while the Essential LBx panel interrogates 34 genes; Fusion LBx interrogates fusion forms from 18 cancer driver genes in cell-free tumor RNA.

支柱的核心LBx小组在循环的无细胞肿瘤DNA中询问104个基因，而基本LBx小组询问34个基因；Fusion LBx询问来自无细胞肿瘤RNA中18个癌症驱动基因的融合形式。

In 2023, Natick, Massachusetts-based Pillar partnered with Illumina to distribute its oncology assays around the world.

2023年，总部位于马萨诸塞州Natick的Pillar与Illumina合作，将其肿瘤学检测方法分发到世界各地。

AstraZeneca also has partnered with several other firms on liquid biopsies, including Angle, Sophia Genetics, IMBdx, and Guardant Health.

阿斯利康还与其他几家公司合作进行液体活检，包括Angle、Sophia Genetics、IMBdx和Guardant Health。